









Markets
/
Stocks
/
nasdaq-zntl
/

Zentalis Pharmaceuticals Inc

ZNTL

1.520USD

+0.030+2.01%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

109.65MMarket Cap

LossP/E TTM



Zentalis Pharmaceuticals Inc

1.520

+0.030+2.01%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

The company's fundamentals are relatively very weak. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a strong stock market performance, the company shows strong fundamentals and technicals, which don't support the current strong trend. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

188 / 506

Overall Ranking

304 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

6.188

Target Price

+315.27%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Zentalis Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing small molecule therapeutics targeting fundamental biological pathways of cancers. The Company’s lead product candidate includes azenosertib (ZN-c3), which is a WEE1 inhibitor for advanced solid tumors and hematological malignancies. The Company is also developing a BCL-2 inhibitor, ZN-d5, for hematological malignancies and related disorders. ZN-d5 is being evaluated in combination with azenosertib in a Phase I/II dose escalation clinical trial in patients with R/R acute myeloid leukemia (AML) (ZN-d5-004C). The Company is also advancing its research on protein degraders and other undisclosed targets using its Integrated Discovery Engine.

Growing

The company is in a growing phase, with the latest annual income totaling USD 67.42M.

Overvalued

The company’s latest PE is -0.67, at a high 3-year percentile range.

Institutional Selling

The latest institutional holdings are 67.79M shares, decreasing 26.62% quarter-over-quarter.

Held by The Vanguard

Star Investor The Vanguard holds 2.88M shares of this stock.

Financial Health

Currency: USD Updated: 2025-09-19

The company's current financial score is 3.95, which is lower than the Biotechnology & Medical Research industry's average of 6.93. Its financial status is weak, and its operating efficiency is low.

Score

Industry at a Glance

Previous score

3.95

Change



Financials

0.00

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

4.76

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

0.00

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

10.00

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

5.00

Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.65, which is 91.21% below the recent high of -1.25 and -543.68% above the recent low of -4.21.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 188/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

The company’s current earnings forecast score is 7.33, which is lower than the Biotechnology & Medical Research industry's average of 8.03. The average price target for Zentalis Pharmaceuticals Inc is 5.50, with a high of 10.00 and a low of 2.50.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

6.188

Target Price

+315.27%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

554

Total

Median

Average

Company name

Ratings

Analysts

Zentalis Pharmaceuticals Inc

ZNTL

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

Intellia Therapeutics Inc

NTLA

Exact Sciences Corp

EXAS

IQVIA Holdings Inc

IQV

...

111

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 4.58, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 1.89 and the support level at 1.24, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.58

Change

0.05

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.060

Sell

RSI(14)

47.046

Neutral

STOCH(KDJ)(9,3,3)

32.088

Buy

ATR(14)

0.112

Low Volatility

CCI(14)

-36.069

Neutral

Williams %R

71.429

Sell

TRIX(12,20)

-0.293

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

1.460

Buy

MA10

1.504

Buy

MA20

1.646

Sell

MA50

1.531

Sell

MA100

1.425

Buy

MA200

1.823

Sell

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 10.00, which is higher than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 93.98%, representing a quarter-over-quarter decrease of 3.47%. The largest institutional shareholder is The Vanguard, holding a total of 2.88M shares, representing 4.00% of shares outstanding, with 12.88% decrease in holdings.

Score

Industry at a Glance

Previous score

10.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Matrix Capital Management Company, LP

13.96M

Walters (William T)

7.05M

+76.25%

Millennium Management LLC

3.07M

-18.82%

The Vanguard Group, Inc.

Star Investors

3.26M

-0.32%

Acadian Asset Management LLC

2.67M

+150.56%

Two Sigma Investments, LP

1.39M

-7.60%

Opaleye Management Inc.

1.99M

+12.31%

Almitas Capital LLC

1.71M

+5.16%

BlackRock Institutional Trust Company, N.A.

3.83M

-0.27%

Tang Capital Management, LLC

1.50M

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.06, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.78. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.